Drug Search Results
More Filters [+]

JTT-251

Alternative Names: jtt-251, jtt251, jtt 251
Latest Update: 2019-05-03
Latest Update Note: Clinical Trial Update

Product Description

PDHK inhibitor; Decreases blood glucose by activation of pyruvate dehydrogenase (PDH) related to carbohydrate metabolism. (Sourced from: https://www.akrospharma.com/pipeline-products/pipe/)

Mechanisms of Action: PDK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Akros Pharma
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for JTT-251

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Familial Primary Pulmonary Hypertension|Hypertension, Pulmonary|Heart Failure, Chronic|Heart Failure, Systolic

Phase 1: Type 2 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RELIEF-PAH

P2

Withdrawn

Hypertension, Pulmonary|Familial Primary Pulmonary Hypertension

2021-03-01

23%

BEAT-CHF

P2

Terminated

Heart Failure, Chronic|Heart Failure, Systolic

2019-04-29

AT251-U-13-001

P1

Completed

Type 2 Diabetes

2014-08-01

Recent News Events

Date

Type

Title